Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Absci's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Absci's regulatory disclosures and financial reporting.
Absci Corp (ABSI) reported that officer Zachariah Jonasson, CFO / CBO, had 8,320 shares of common stock withheld on 2026-08-31 to cover a tax withholding obligation related to the vesting of restricted stock units. This was a non-discretionary tax-withholding disposition, and Jonasson now directly holds 483,144 common shares.
Absci Corporation reported continued operating losses while advancing its AI-driven biologics pipeline in the quarter ended June 30, 2026. Partner program revenue declined to $0.3 million for the quarter and $0.5 million for the first half of 2026, down sharply from 2025 due to milestone timing and program mix. Net loss widened to $33.2 million for the quarter and $62.8 million year-to-date, driven mainly by higher research and development spending as lead antibody ABS-201 progresses through clinical development.
Absci strengthened its balance sheet with a June 2026 public equity offering that raised approximately $93.6 million net and additional at-the-market sales, bringing cash, cash equivalents and marketable securities to $201.1 million as of June 30, 2026. Management believes this provides funding for at least 12 months. The company highlighted its AI-native Integrated Drug Creation platform and early clinical progress of ABS-201, including positive interim Phase 1 safety data and a long estimated half-life supporting infrequent dosing, while emphasizing that it remains in early stages with no milestone or royalty revenue yet realized.
Absci Corporation reported second-quarter 2026 results and pipeline updates. Revenue from partner programs was $0.3 million for the quarter ended June 30, 2026, compared with $0.6 million a year earlier. Research and development expenses rose to $22.6 million from $20.5 million, and selling, general, and administrative expenses increased to $9.2 million from $8.5 million. Net loss widened to $33.2 million from $30.6 million.
Cash, cash equivalents, and marketable securities were $201.1 million as of June 30, 2026, up from $125.7 million as of March 31, 2026, reflecting $93.6 million of net proceeds from a $100 million underwritten offering that included a $40 million strategic equity investment from Eli Lilly & Company. Absci now believes this cash position will fund operating plans into the second half of 2028.
Absci highlighted positive interim Phase 1 data from the HEADLINE trial of ABS-201 for pattern hair loss, with blinded data suggesting the drug was well tolerated and an estimated half-life of at least 65 days, supporting potential dosing two or three times over six months. The company anticipates interim proof-of-concept data for pattern hair loss in the second half of 2026, full proof-of-concept data in early 2027, and initiation of a Phase 2 trial of ABS-201 for endometriosis in the fourth quarter of 2026.
Absci Corp reported that its CMO and Head of R&D, Ransi Mudalinayake, received two grants of employee stock options. One grant covers 383,000 options with a $7.93 exercise price expiring on August 2, 2036, and another covers 650,000 options at $2.57 expiring on March 2, 2036. For each grant, 25% of the shares vest on the first anniversary of the grant date, with the remaining shares vesting in 36 approximately equal monthly installments, subject to continued service.
Absci Corp filed an initial statement of beneficial ownership for officer Somaratne Ransi Mudalinayake, who serves as CMO and Head of R&D. The report lists no transactions and shows no Absci securities reported as beneficially owned, establishing a baseline ownership position for this new reporting person.
Absci Corp director Mary T. Szela made an open-market purchase of 12,900 shares of Common Stock at $11.54 per share on June 30, 2026. After this transaction, she directly owns 21,300 shares. The trade was executed in accordance with the issuer's trading policies.
Absci Corp Chief Executive Officer Sean McClain reported a tax-related share disposition tied to restricted stock vesting. On this Form 4, 59,896 shares of common stock were withheld by the company at $10.075 per share to cover tax obligations arising from the vesting of 150,000 performance-based RSUs triggered by a $10.00 stock price condition. After this non-discretionary withholding, McClain directly holds 8,655,555 shares of Absci common stock.
Absci Corporation has priced an underwritten public offering of 13,495,277 shares of its common stock. The shares are being sold at $7.41 per share, for expected gross proceeds of about $100 million and estimated net proceeds of approximately $93.5 million after fees and expenses.
All shares are being sold by Absci under an effective shelf registration statement on Form S-3. The company plans to use the net proceeds primarily to advance ABS-201, its AI-designed anti-PRLR antibody program for androgenetic alopecia and endometriosis, and for working capital and general corporate purposes.
Absci Corporation is offering 13,495,277 shares of common stock at $7.41 per share. The prospectus supplement states that 5,398,111 of those shares have been allocated for purchase by Eli Lilly and Company for an aggregate offering price of $40 million. The underwritten offering is expected to deliver shares on or about June 25, 2026, and the company estimates net proceeds of approximately $93.5 million. The supplement cites 155,350,135 shares outstanding as of March 31, 2026 as the baseline for dilution calculations and discloses immediate dilution to new investors of $6.08 per share based on as adjusted net tangible book value.
Use of proceeds is stated as funding advancement of ABS-201 across androgenetic alopecia and endometriosis, working capital and general corporate purposes; timing and allocation remain at management’s discretion.
Absci Corporation reported positive interim Phase 1 results for ABS-201 from its HEADLINE trial in healthy adults with and without androgenetic alopecia. In four single ascending dose cohorts totaling 32 participants, intravenous ABS-201 at 150, 450, 900, and 1800 mg appeared well tolerated with no serious adverse events reported.
Most treatment-emergent adverse events were mild; one moderate headache was assessed as unlikely related to treatment. Interim pharmacokinetic data indicate an estimated half-life of at least 65 days, supporting a potential dosing schedule of two or three injections over six months. The study has advanced into a subcutaneous multiple ascending dose phase in androgenetic alopecia participants, with interim proof-of-concept data expected in the second half of 2026 and full proof-of-concept data in early 2027.